RVMD is the clear winner, but the bigger mechanism is a lower cost of capital for the entire RAS-pathway stack. The market will likely stop treating RAS inhibition as a science project and start underwriting it as a platform with line-of-sight to lung and colorectal expansion; that can re-rate late-stage oncology assets while pressuring adjacent programs built on the assumption that direct RAS remains technically elusive. Near term, the biggest second-order effect is not pancreatic revenue, but a shift in investor willingness to fund combination trials and earlier-line development.

The consensus may be overestimating how quickly this converts into broad commercial upside. Pancreatic cancer is a proof point, not a TAM; the real valuation inflection depends on durability, tolerability, and whether insurers allow off-label use outside the labeled setting without forcing prior auth or step edits. If safety is manageable, the FDA precedent also modestly reduces regulatory discount for other oncology readouts, but it does not eliminate the evidence burden for combination regimens or biomarkers.

Time horizon matters: the stock can keep working for days to weeks on validation and launch momentum, but the 1-3 month path will be driven by prescribing velocity, discontinuation rates, and any signal on combo-trial sequencing. The contrarian risk is a "buy the platform, sell the actual product" setup if investors extrapolate a small first-indication launch into a much larger NPV than reimbursement and resistance biology justify. What would falsify the thesis is weak early refill/persistence, payer friction, or a safety profile that limits combination use; in that case, the market will quickly revert to valuing RVMD as a single-asset story rather than a category creator.